Systematic proteome-wide Mendelian randomization using the human plasma proteome to identify therapeutic targets for lung adenocarcinoma

Table 1 Data sources for the Mendelian randomization analysis in the study

Phenotype	Sample size	Ancestry	Sources
Plasma protein
deCODE (primary)	4907	Icelander	Ferkingstad, et al. [14]
UKB-PPP (validation)	33,469	European	Sun et al. [25]
Outcomes
LUAD (primary)	11,245/54619	European	TRICL [20,21,22,23,24]
LUAD (validation)	1553/287137	European	FinnGen Cohort [26]
Risk factors
Age of smoking initiation	341,427	European	Liu, et al. [27]
Number of cigarettes smoked daily	108,946	European	UK Biobank
Pack years of smoking	142,387	European	UK Biobank
Maternal smoking around birth	121,634/276098	European	UK Biobank
Any parental history of lung cancer	407,521	European	Mbatchou J [28]
Average weekly beer intake	327,634	European	UK Biobank
Leisure activities	67,877/393492	European	UK Biobank
COPD	13,530/454945	European	Sakaue et al. [29]

Samplesize shown as a total number for quantitative traits and cases/controls for binary traits
TRICL: Transdisciplinary Research in Cancer of the Lung; PLCO: Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. LUAD: lung adenocarcinoma; COPD: chronic obstructive pulmonary disease

ISSN: 1479-5876